Education
About Us
Working with TipRanks
Follow Us
Capricor Therapeutics, Inc. (CAPR)
NASDAQ:CAPR
CAPR Stock Chart & Stats
$24.50
-$0.36(-2.53%)
At close: 4:00 PM EST
$24.50
-$0.36(-2.53%)
Day’s Range― - ―
52-Week Range$4.30 - $40.37
Previous CloseN/A
Volume187.65K
Average Volume (3M)1.13M
Market Cap
$1.33B
Enterprise Value$1.12B
Total Cash (Recent Filing)$98.57M
Total Debt (Recent Filing)$14.54M
Price to Earnings (P/E)―
Beta2.38
Next Earnings
Mar 25, 2026EPS Estimate
-0.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.54
Shares Outstanding54,400,784
10 Day Avg. Volume1,116,377
30 Day Avg. Volume1,125,774
Financial Highlights & Ratios
PEG Ratio-0.31
Price to Book (P/B)3.34
Price to Sales (P/S)21.82
P/FCF Ratio-11.70
Enterprise Value/Market Cap0.84
Enterprise Value/Revenue100.18
Enterprise Value/Gross Profit-17.22
Enterprise Value/Ebitda-13.40
Forecast
1Y Price Target
$52.88Price Target Upside115.84% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)0.32
Revenue Forecast (FY)$138.40M
Bulls Say, Bears Say
Bulls Say
Clinical Trial EfficacyHOPE-3 topline reportedly met primary and key secondary endpoints with skeletal and cardiac benefits and a favorable safety profile, supporting meaningful therapeutic value for DMD patients.
Commercial And Financing UpsideRare Pediatric Disease Priority Review Voucher potential and expanded partnership interest from Nippon Shinyaku could provide a significant source of cash or commercial support if eligibility and agreements materialize.
Regulatory EngagementFDA requested the full clinical study report but did not request new clinical trials or additional patient data, indicating constructive regulatory engagement that could advance the review process.
Bears Say
Investor Uncertainty And Share VolatilityShares may experience significant volatility as investors seek definitive FDA feedback and clarity on the path forward after prior regulatory setbacks.
Priority Voucher Legal RiskEligibility for the Priority Review Voucher is uncertain due to possible legislative changes, creating a material risk to the anticipated cash benefit.
Trial Composition And Manufacturing ConcernsOutstanding questions about trial population composition, representation of background cardiac medications, and manufacturing controls could prompt additional data requests or regulatory delays.
Capricor Therapeutics News
CAPR FAQ
What was Capricor Therapeutics, Inc.’s price range in the past 12 months?
Capricor Therapeutics, Inc. lowest stock price was $4.30 and its highest was $40.37 in the past 12 months.
What is Capricor Therapeutics, Inc.’s market cap?
Capricor Therapeutics, Inc.’s market cap is $1.33B.
When is Capricor Therapeutics, Inc.’s upcoming earnings report date?
Capricor Therapeutics, Inc.’s upcoming earnings report date is Mar 25, 2026 which is in 48 days.
How were Capricor Therapeutics, Inc.’s earnings last quarter?
Capricor Therapeutics, Inc. released its earnings results on Nov 10, 2025. The company reported -$0.54 earnings per share for the quarter, beating the consensus estimate of -$0.547 by $0.007.
Is Capricor Therapeutics, Inc. overvalued?
According to Wall Street analysts Capricor Therapeutics, Inc.’s price is currently Undervalued.
Does Capricor Therapeutics, Inc. pay dividends?
Capricor Therapeutics, Inc. does not currently pay dividends.
What is Capricor Therapeutics, Inc.’s EPS estimate?
Capricor Therapeutics, Inc.’s EPS estimate is -0.51.
How many shares outstanding does Capricor Therapeutics, Inc. have?
Capricor Therapeutics, Inc. has 54,400,784 shares outstanding.
What happened to Capricor Therapeutics, Inc.’s price movement after its last earnings report?
Capricor Therapeutics, Inc. reported an EPS of -$0.54 in its last earnings report, beating expectations of -$0.547. Following the earnings report the stock price went up 11.511%.
Which hedge fund is a major shareholder of Capricor Therapeutics, Inc.?
Currently, no hedge funds are holding shares in CAPR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Capricor Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$52.88 (115.84% Upside)
$52.88 (115.84% Upside)
Blogger Sentiment
Bullish
CAPR Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 231.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 5.4%
Last 30 Days ▲ 1.0%
Last 30 Days ▲ 1.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
62.57%
12-Months-Change
Fundamentals
Return on Equity
-107.79%
Trailing 12-Months
Asset Growth
36.03%
Trailing 12-Months
Company Description
Capricor Therapeutics, Inc.
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.
CAPR Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in the clinical development of Daramycin and operational readiness for commercialization. However, financial challenges were evident with zero revenue in 2025 and increased operating expenses, alongside the need to address regulatory hurdles following a CRL.View all CAPR earnings summariesCAPR Stock 12 Month Forecast
Average Price Target
$52.88
▲(115.84% Upside)
Technical Analysis
Ownership Overview
1.08% Insiders
5.79% Mutual Funds
<0.01% Other Institutional Investors
86.56% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---